Search global stocks & ETFs...Ctrl K
Learn Mode
TEM logo
Tempus AI IncTEM
$60.27
-$1.33 (-2.159%)
at close
$60.06
-$0.21 (-0.345%)
after hours · 11:50 PM
General
Scores
Financials & KPIs
Dividends
Analyst
Insider
Updates
TEM
Stock Profile
Market Cap
$10.82B
Industry
Life Sciences Tools & Services
EPS (TTM)
-$1.69
P/E (TTM)
0.00
Div & Yield
--
FCF Payout Ratio
--
P/S (TTM)
7.93
P/B
25.99
Revenue Growth (TTM)
69.82%
EPS CAGR (3Y)
0.00%
Diluted Shares
178.88M
Ex-Dividend
--
Next Earnings
07-31
Forward P/E
0.00
Payout Ratio
--
P/FCF (TTM)
0.00
FCF Yield
--
Earnings Yield
-2.80%
Revenue CAGR (3Y)
65.68%
Recommended Metric
--
Tempus AI Inc has a current cash runway of 34.91 months. The cash runway is the amount of time the business has at its current burn rate before it will need to take on debt or dilute shareholders to raise more money. However, it has grown revenue at 69.82% over the past year, which is strong growth.
Valuation Score
Key Score
--
--
Management
5.00
Very Good

Growth
1.00
Very Bad

Profitability
4.00
Good
Fin. Health
2.00
Bad

Dividends
--
--

Analyst
3.00
Average
Revenue
Earnings
Free Cash Flow
Insider Transactions
Explore Insider Tab ›
Buy Transactions
Sell Transactions
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$60.27
Baseline
High
$105.00
74.22%
Avg
$72.38
20.10%
Low
$35.35
-41.35%
Analyst Ratings based on 23 Analysts
Strong Buy
5
22%
Buy
9
39%
Hold
7
30%
Sell
1
04%
Strong Sell
1
04%
Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. The company is headquartered in Chicago, Illinois and currently employs 3,800 full-time employees. The company went IPO on 2025-05-30. The company offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. The company provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.Read More

IPO Date
2025-05-30

Industry
Life Sciences Tools & Services

Total Employees
3,800

Exchange
Nasdaq Nms - Global Market

Reporting Currency
USD

GICS
Life Sciences Tools & Services

GICS Sub
Life Sciences Tools & Services

GICS Sector
Health Care

GICS Group
Pharmaceuticals, Biotechnology & Life Sciences